At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Placebo-controlled, Parallel-group, Investigator- and Participant-blinded Phase 2a Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in an Adult Population With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP)
In Brief
A Phase 2 clinical trial evaluating MAS825, MAS825 Placebo, and 2 other interventions for Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP). Completed, enrolled 31 participants across 6 sites in 3 countries.
Detailed Summary
This Phase 2a clinical trial evaluated the effectiveness, safety, and tolerability of increasing dose strengths of an oral daily medication, DFV890, administered for 12 weeks, or a single s.c. dose of MAS825, to reduce key markers of inflammation related to CVD risk, such as IL-6 and IL-18, in approximately 28 people with known coronary heart disease and TET2 or DNMT3A CHIP (variant allele frequency \[VAF\] ≥2%).
Study Details
Timeline
Interventions
Active MAS825 single dose
MAS825 placebo single dose
Oral tablet of DFV890 active once daily
Oral tablet of DFV890 placebo once daily